Every peptide we carry. Sixteen vials, one standard.

Triple-agonist GLP-1, GIP, and glucagon receptor agonist studied for body-weight reduction in clinical trials.

Dual GLP-1/GIP peptide with extensive brand-drug trial history; research-grade tirzepatide, including ours, is not an approved medicine.

Pentadecapeptide studied for soft-tissue repair and gut-lining endpoints. The published record is largely preclinical.

Growth-hormone secretagogue blend studied for growth-hormone release, sleep-depth and recovery endpoints.

Copper tripeptide studied for dermal collagen synthesis, skin renewal and wound-healing endpoints.

Thymosin beta-4 fragment studied for soft-tissue and muscle repair endpoints.

Melanocortin agonist studied for melanogenesis and pigmentation with reduced UV exposure.

Russian-developed nootropic peptide studied for attention, memory and BDNF expression.

Neuropeptide studied for calm and focus support without sedative framing. Evidence base is still developing and varies by study type.

Four peptides in one vial: BPC-157, TB-500, GHK-Cu and KPV. Each is studied separately for tissue-repair or skin endpoints; the combination itself has no published trial.

Mitochondrial peptide studied for cellular energy and metabolic signaling in early research.

Pineal-derived tetrapeptide studied for telomerase activation, sleep-onset latency and circadian endpoints.

GHRH analog studied for visceral-fat endpoints, with brand-drug clinical history for a specific indication. Research-grade tesamorelin, including ours, is not an approved medicine.

Exercise mimetic studied as an ERR receptor agonist, with endurance and fat-oxidation endpoints reported. Studied as a pharmacological proxy for training effects.

Melanocortin agonist studied for sexual-arousal endpoints in both sexes. Acts centrally rather than vascularly, unlike the PDE5 class.

Antioxidant tripeptide studied for redox balance, detoxification pathways and skin endpoints.